Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C

By Takaki Shintaro   Tsubota Akihito   Hosaka Tetsuya   Akuta Norio   Someya Takashi   Kobayashi Masahiro   Suzuki Fumitaka   Suzuki Yoshiyuki   Saitoh Satoshi   Arase Yasuji   Ikeda Kenji   Kumada Hiromitsu  

Journal of Gastroenterology, Vol. 39, Iss. 7, 2004-07 ,pp. : 668-673

Springer Publishing Company

Access to resources Recommend Favorite

Response to Combination Therapy with Interferon Alfa-2a and Ribavirin in Chronic Hepatitis C According to a TNF-α Promoter Polymorphism

By  

Digestion, Vol. 68, Iss. 1, 2003-10 ,pp. : 1-4

Karger

Access to resources Recommend Favorite

From Trials to a Real Hospital Setting: Effectiveness of Pegylated Interferon-α-2b/Ribavirin Combination Therapy for Naïve Chronic Hepatitis C Patients

By Piai Guido   Scalice Elisa   Focareta Rosaria   Terracciano Fulvia   Filippo Francesca   Forte Giovambattista  

Digestive Diseases and Sciences, Vol. 51, Iss. 9, 2006-09 ,pp. : 1619-1626

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Benefits and Cost-Effectiveness of 17-Year Treatment with Low-Dose Interferon-α 2b in a Patient with Chronic Hepatitis C: A Case Report

By Kawaguchi Takumi   Sumie Shuji   Itou Minoru   Taniguchi Eitaro   Matoba Tsunetaka   Sata Michio  

Digestive Diseases and Sciences, Vol. 54, Iss. 3, 2009-03 ,pp. : 690-694

Springer Publishing Company

Access to resources Recommend Favorite

Pegylated Interferon α-2b, Ribavirin and Amantadine for Chronic Hepatitis C

By Younossi Zobair   McCullough Arthur   Barnes David   Post Anthony   Ong Janus   O’shea Robert   Martin Lisa   Bringman Diane   Farmer Denise   Levinthal Gavin   Mullen Kevin   Carey William   Tavill Anthony   Ferguson Roy   Gramlich Terry  

Digestive Diseases and Sciences, Vol. 50, Iss. 5, 2005-05 ,pp. : 970-975

Springer Publishing Company

Access to resources Recommend Favorite